Catheter Ablation -> Atrial Fibrillation & Atrial Flutter: -> Clinical Trials / Outcomes D-PO03 - Poster Session III (ID 48) Poster

D-PO03-188 - The Outcomes Of Peri-procedural Corticosteroid Therapy For Preventing Early Recurrence Of Atrial Fibrillation After Cryoballoon Catheter Ablation (ID 357)

Abstract

Background: Cryoballoon (CB) ablation for atrial fibrillation (AF) creates larger lesion in the left atrium compared to conventional radiofrequency pulmonary vein isolation (PVI). Inflammatory reactions of ablation lesion creation are highly related to early recurrence of AF(ERAF) after catheter ablation. To the date, the effect of corticosteroid therapy on suppressing ERAF after cryoballoon ablation has not been clear.
Objective: The objective of this study was to investigate the efficacy of peri-procedural corticosteroid therapy for preventing ERAF after CB ablation.
Methods: 39 consecutive paroxysmal AF patients who underwent PVI using 2nd generation cryoballoon catheter were investigated. CB ablation was performed using standard protocols, freeze of 180 sec or additional 60 sec freeze after electrical PVI. Anti-arrhythmic drugs were continued during 2 months blanking period. Intravenous hydrocortisone (2 mg/kg) was given immediately after CB ablation, and oral prednisolone (0.5 mg/kg/day) administration was followed for 2 days after the PVI in corticosteroid group. The outcomes of early recurrence of AF (AF recurrence ≤3days after ablation and during blanking periods) and inflammatory parameters including body temperature (BT) and serum C-reactive protein (CRP) level were compared.
Results: Eleven of 39 patients were received peri-procedural corticosteroid therapy. Acute electrical isolation of all PVs was achieved in all patients. Number and duration of freeze and the prevalence of non PV AF foci were not different between the groups. Inflammatory parameters was not different between the groups. The incidence of immediate AF recurrence (≤3 days after ablation) was significantly lower in the corticosteroid group than in the control (0% vs. 28%, p=0.047), and ERAF was also significantly lower in the corticosteroid group(0% vs. 35%, p=0.022) .The incidence of adverse event such as procedural complications, infection and digestive ulcer was not different between groups.
Conclusion: Peri-procedural corticosteroid therapy immediately after CB ablation effectively prevented both immediate AF recurrence and ERAF. Further investigation including long-term outcomes is required to clarify the findings in the present study.
Collapse